- Home
- AMBO vs MBIO Comparison
AMBO vs MBIO Comparison
Compare AMBO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- MBIO
- Stock Information
- Founded
- AMBO 2000
- MBIO 2015
- Country
- AMBO United States
- MBIO United States
- Employees
- AMBO N/A
- MBIO N/A
- Industry
- AMBO Other Consumer Services
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- MBIO Health Care
- Exchange
- AMBO Nasdaq
- MBIO Nasdaq
- Market Cap
- AMBO 7.2M
- MBIO 7.3M
- IPO Year
- AMBO 2010
- MBIO N/A
- Fundamental
- Price
- AMBO $2.65
- MBIO $2.95
- Analyst Decision
- AMBO
- MBIO Strong Buy
- Analyst Count
- AMBO 0
- MBIO 1
- Target Price
- AMBO N/A
- MBIO $100.00
- AVG Volume (30 Days)
- AMBO 24.5K
- MBIO 374.6K
- Earning Date
- AMBO 12-30-2024
- MBIO 03-10-2025
- Dividend Yield
- AMBO N/A
- MBIO N/A
- EPS Growth
- AMBO N/A
- MBIO N/A
- EPS
- AMBO N/A
- MBIO N/A
- Revenue
- AMBO $7,839,000.00
- MBIO N/A
- Revenue This Year
- AMBO N/A
- MBIO N/A
- Revenue Next Year
- AMBO N/A
- MBIO N/A
- P/E Ratio
- AMBO N/A
- MBIO N/A
- Revenue Growth
- AMBO N/A
- MBIO N/A
- 52 Week Low
- AMBO $1.00
- MBIO $2.40
- 52 Week High
- AMBO $5.55
- MBIO $74.50
- Technical
- Relative Strength Index (RSI)
- AMBO 54.68
- MBIO 32.04
- Support Level
- AMBO $2.34
- MBIO $2.58
- Resistance Level
- AMBO $2.80
- MBIO $2.95
- Average True Range (ATR)
- AMBO 0.31
- MBIO 0.36
- MACD
- AMBO -0.02
- MBIO 0.18
- Stochastic Oscillator
- AMBO 63.82
- MBIO 29.26
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.